SIStockInvestingSI.com

NYSE · DHR · Diagnostics & Research

Danaher (DHR) stock analysis

$233.86+4.29%Data as of Oct 21, 2026
  • DHR gained 6.0% over the past month versus 0.0% for the S&P 500, ranking 155th of 497 S&P 500 stocks.
  • Over 12 months it returned +12.6%, 3.2 points behind the S&P 500, and trades 3.2% below its 52-week high.
  • In the last 30 days 5 analysts raised earnings estimates and 2 cut; forward EPS moved 0.0% (+0.4% over 90 days).
  • It sits in the Life-science tools & bioprocessing segment of the Healthcare Value Chain, where the 1-month median return is +6.0%.
  • The daily chart reads Intermediate uptrend · Failed breakout (since Oct 19, 2026).
Market cap$164.4B
12-month return+12.6%
Forward P/E25.1×
Mean target vs price+5.7%

One-year price with 50- and 200-day averages

Open in Hub
168191213236JanAprJulOct
224.2450-day200-day

Performance vs the market

Total price return against the S&P 500 (SPY) and the median of US stocks in the same sector.

DHR+6.0%
Sector median−8.7%
S&P 5000.0%
DHR+21.5%
Sector median−5.4%
S&P 500+4.7%
DHR+27.1%
Sector median−1.5%
S&P 500+8.7%
DHR+12.6%
Sector median+1.7%
S&P 500+15.8%
1-month rank in the S&P 500155 / 497
3-month rank in its sector · Healthcare136 / 720

Chart structure

Read by our daily-bar structure engine from swing highs, swing lows and moving averages.

Intermediate uptrend · Failed breakoutFailed

Holding since Oct 19, 2026

  • Close above EMA20 above EMA50
  • EMA50 rose over the last ten sessions
  • Volume exceeds 1.5× the prior 20-session average; supporting evidence only
This pattern on this stock

11 occurrences in 10 years. The median move over the next 20 sessions was +0.9%, positive 55% of the time, against +1.2% for any day in the same period.

Reference zone, stop and targets for this structureSee the trade plan in Hub ↗

Analyst earnings revisions

Changes to the consensus forward-EPS estimate. Rising estimates mean analysts see more profit ahead.

Forward EPS$9.30
30-day change0.0%
90-day change+0.4%
Mean target$247.18 +5.7%
Raised (30d) 5Cut (30d) 2

22 analysts cover the stock

Fundamental shape vs peers

Six dimensions on fixed scales. The filled shape is the company; the outline is the peer average.

Open the full Radar with every ratio
ValuationRevisionsMomentumGrowthCashProfit

Ahead of peersRevisions

Behind peersMomentum

PeersTMO · NTRA · A · IQV

Where it sits in the supply chain

Healthcare Value Chain · Tools & research

Explore the full chain map in Hub
Its segment
Life-science tools & bioprocessing+6.0%
TMO+5.4%1 monthDHR+6.0%1 monthA+6.4%1 month

Instruments, reagents and bioprocessing consumables, following pharma R&D and biologics capacity; biotech funding conditions matter a lot.

Sells into
Obesity & metabolic (GLP-1)+3.8%
LLY+8.6%1 monthNVO−0.9%1 month
Large pharma−0.7%
JNJ−4.2%1 monthMRK−0.7%1 monthABBV+7.4%1 monthPFE+6.9%1 monthBMY−0.8%1 month
Biotech+0.4%
AMGN+6.8%1 monthREGN+0.2%1 monthGILD+0.6%1 monthVRTX+1.9%1 monthALNY−10.6%1 monthMRNA+34.6%1 monthBIIB+6.9%1 monthINSM−22.2%1 monthINCY−10.6%1 monthCATX−22.3%1 month

Also on: Medtech, Diagnostics & Care

Figures are each company's 1-month return; the segment shows its median · Doubler daily batch · company chain maps

Risk profile

Max drawdown, 12M−33.0%
Volatility, 60D29.0%
From 52-week high−3.2%
From 52-week low+44.4%
Trailing P/E41.7×
Forward P/E25.1×
TMOThermo Fisher ScientificAAgilent Technologies, Inc.LLYEli LillyJNJJohnson & JohnsonMRKMerckABBVAbbViePFEPfizerBMYBristol Myers Squibb

Track this stock every day

Hub adds the daily brief, StockFlow factor flow, trade plans and alerts for your watchlist.

Open in Hub ↗